Edwards Lifesciences (NYSE:EW) Releases Earnings Results, Beats Estimates By $0.04 EPS

by · The Markets Daily

Edwards Lifesciences (NYSE:EW – Get Free Report) released its quarterly earnings results on Thursday. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04, FiscalAI reports. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same period last year, the business posted $0.67 EPS. The company’s revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences updated its Q3 2026 guidance to 0.710-0.770 EPS and its FY 2026 guidance to 2.950-3.050 EPS.

Here are the key takeaways from Edwards Lifesciences’ conference call:

  • Edwards reported second-quarter sales growth of 12.5% to $1.74 billion, topping expectations and reflecting strength across all product groups and regions.
  • Management raised full-year 2026 guidance for total company sales to 10%-11%, TAVR sales to 8%-9%, and TMTT revenue to $760 million-$780 million, while reaffirming adjusted EPS of $2.95-$3.05.
  • TAVR delivered stronger-than-expected sales of $1.3 billion, with management citing continued SAPIEN adoption, stable pricing, favorable clinical data, and support from competitor exit dynamics. The company also highlighted first patients treated with the next-gen SAPIEN X4-S and expects the final CMS NCD policy in September.
  • TMTT was a major growth driver, with sales up 44.8% year over year to $195.9 million as PASCAL, EVOQUE, and SAPIEN M3 all contributed. Edwards expects additional catalysts from next-gen PASCAL approvals, U.S. tricuspid launch, and broader EVOQUE and M3 scaling.
  • Management also pointed to a strong surgical business, with sales up 5% and new evidence supporting RESILIA durability, plus U.S. approval of ECLIPTIS. However, the call emphasized that U.S. tax changes and FX headwinds will pressure margins and raise the effective tax rate near the high end of guidance.

Edwards Lifesciences Stock Performance

Shares of NYSE EW opened at $83.63 on Friday. The firm has a fifty day moving average price of $87.70 and a 200-day moving average price of $83.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The stock has a market cap of $48.15 billion, a PE ratio of 44.48, a price-to-earnings-growth ratio of 2.12 and a beta of 0.86. Edwards Lifesciences has a 1 year low of $72.30 and a 1 year high of $96.29.

Wall Street Analysts Forecast Growth

EW has been the topic of a number of recent research reports. Evercore reissued an “outperform” rating and issued a $100.00 target price on shares of Edwards Lifesciences in a report on Monday, July 6th. Barclays restated an “overweight” rating and set a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Mizuho increased their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 15th. Wall Street Zen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Finally, TD Cowen restated a “buy” rating on shares of Edwards Lifesciences in a research report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat, Edwards Lifesciences has a consensus rating of “Moderate Buy” and a consensus target price of $99.04.

Check Out Our Latest Stock Analysis on EW

Insider Activity at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the transaction, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $83.01, for a total value of $84,587.19. Following the sale, the vice president owned 33,934 shares of the company’s stock, valued at $2,816,861.34. This represents a 2.92% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 45,577 shares of company stock worth $3,855,527. 0.31% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. JPL Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the third quarter valued at approximately $25,000. Kemnay Advisory Services Inc. bought a new position in shares of Edwards Lifesciences during the fourth quarter worth $27,000. Rakuten Securities Inc. boosted its position in shares of Edwards Lifesciences by 413.7% during the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after acquiring an additional 302 shares during the last quarter. Kelleher Financial Advisors purchased a new position in Edwards Lifesciences during the third quarter valued at $50,000. Finally, Chapman Financial Group LLC purchased a new position in Edwards Lifesciences during the second quarter valued at $63,000. 79.46% of the stock is currently owned by institutional investors.

Key Headlines Impacting Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

  • Positive Sentiment: Leerink Partners upgraded Edwards Lifesciences (EW) from market perform to outperform and set a $101 price target, implying meaningful upside from recent levels. Leerink Partners upgrade
  • Positive Sentiment: The company reported strong Q2 results, with revenue up 13.6% year over year to $1.74 billion and adjusted EPS of $0.78, both ahead of Wall Street estimates. Q2 results press release
  • Positive Sentiment: Management raised its full-year sales outlook to $6.6 billion-$6.9 billion and increased the low end of guidance, signaling confidence in continued demand for its heart-valve and transcatheter therapies. WSJ guidance update
  • Positive Sentiment: Investors also responded favorably to strong sales momentum in the core TAVR franchise and improving expectations for TMTT, which helped push the stock up in extended trading after the earnings release. Reuters earnings article
  • Neutral Sentiment: Analysts’ recent coverage remains constructive overall, with multiple firms maintaining or issuing positive targets around the $100-$110 range, reinforcing a favorable sentiment backdrop for the stock. Analyst targets overview

Edwards Lifesciences Company Profile

(Get Free Report)

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Featured Articles